Study Evaluating How Retratrutide Affects Heart Health and Kidney Function in People Who Have Heart Disease and/or kidney Disease
This study wants to learn if retatrutide works better than a placebo at lowering the risk of serious heart problems and slowing kidney damage in people with body mass index of 27 or higher.
Why this Research Matters
We are testing retatrutide, an investigational drug, to see if it is safe and how well it works in people who are overweight and have heart and/or kidney related diseases as compared to a placebo. Investigational means that retratrutide is still being studied and is not yet approved by the FDA. A placebo looks the same as and is given the same as the study drug but has no active ingredients.
If you join this study, you will be randomly chosen to get either the study drug (retatrutide) or the placebo. This means you won’t get to pick which one you get, like flipping a coin. You will need to take the study drug as a shot once a week. During the study, we will check your vitals, height, weight, and waist size. We will also ask about your medical history and have you fill out surveys. We will take a small amount of blood from your arm with an IV up to 15 times and collect your urine.
You will have 15 study visits at CU Anschutz Medical Campus, and the study will last about 5 years.
You may join this study if you:
- Are 45 years or older
- Have a body mass index of 27 or higher
- Have heart or kidney disease
The study team will check other requirements at your first visit.
You will get up to $140 for each study visit you complete.
